Richard Lirio to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Richard Lirio has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.922
-
Peyrin-Biroulet L, Loftus EV, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology. 2021 10; 161(4):1156-1167.e3.
Score: 0.651
-
Hyams JS, Turner D, Cohen SA, Szakos E, Kowalska-Duplaga K, Ruemmele F, Croft NM, Korczowski B, Lawrence P, Bhatia S, Kadali H, Chen C, Sun W, Rosario M, Kabilan S, Treem W, Rossiter G, Lirio RA. Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. J Crohns Colitis. 2022 Aug 30; 16(8):1243-1254.
Score: 0.177
-
Chen J, Girard M, Wang S, Kisfalvi K, Lirio R. Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients. J Biopharm Stat. 2022 03; 32(2):330-345.
Score: 0.168
-
Wyant T, Yang L, Lirio RA, Rosario M. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. J Clin Pharmacol. 2021 09; 61(9):1174-1181.
Score: 0.164
-
Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J, Lin T, McKnight S, Kadali H, Rosario M, Lirio RA. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021 06; 60(6):811-818.
Score: 0.159
-
Sun W, Lirio RA, Schneider J, Aubrecht J, Kadali H, Baratta M, Gulati P, Suri A, Lin T, Vasudevan R, Rosario M. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. Clin Pharmacol Drug Dev. 2021 07; 10(7):734-747.
Score: 0.157
-
Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
Score: 0.154
-
Sands BE, Schreiber S, Lirio RA. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply. N Engl J Med. 2020 01 02; 382(1):93-94.
Score: 0.147
-
Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, T?r?ner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1215-1226.
Score: 0.144